Brief: UNITY Biotechnoogy Announces Design Of Phase 2B ASPIRE Study Evaluating UBX1325 In Diabetic Macular Edema
21/06/2023 12:06
June 21 (Reuters) - UNITY Biotechnology Inc UBX.O :
* UNITY ANNOUNCES DESIGN OF PHASE 2B ASPIRE STUDY EVALUATING
UBX1325 IN DIABETIC MACULAR EDEMA (DME)
* UNITY BIOTECHNOLOGY - EXPECTS TO BEGIN ACTIVATING CLINICAL
TRIAL
SITES FOR PHASE 2B ASPIRE STUDY IN Q3 AND DOSE FIRST PATIENT IN
Q4 OF 2023
* UNITY BIOTECHNOLOGY - WITH CURRENT TIMELINES, LAST PATIENT
VISIT
EXPECTED TO BE IN Q4 2024, WITH 16- AND 24-WEEK DATA READOUTS
ANTICIPATED IN Q1 2025
Source text for Eikon: ID:nGNXbV9XM9
Further company coverage: UBX.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Unity Biotechnology
See all newsU.S. STOCKS ON THE MOVE-Eve Holding, Magnite, EHang Holdings
U.S. STOCKS ON THE MOVE-Lamb Weston, Robinhood, Eve Holding
Unity Biotechnology slips as co faces Nasdaq delisting, plans dissolution
Brief: Unity Biotechnology Inc - Board Approves Plan Of Dissolution - SEC Filing
Brief: UNITY Biotechnology Estimates $3.7 Million Expenses For Reduction In Force